Thursday, October 29, 2026

Second edition of 'Rollercoaster,' tribute to wife, musical genius, and muse on sale at 2015 prices

The second edition of a book that's a tribute to a wife, musical genius and muse — as well as a deep dive into her brave fight against breast cancer, three times over three decades — has just been published.

Rollercoaster: How a caregiver can survive a partner's breast cancer or any other lethal disease can be purchased at prices that date to 2015, when the first edition was launched. Buy-buttons on https://woodyweingarten.com/ can take you directly to Barnes & Nobel, Apple, Amazon and a lot more choices of vendors.

Woody Weingarten
The book, a love story and a tribute to Nancy Fox by her husband, Woody Weingarten, contains a totally revamped chapter on meds, another on treatments, an updated segment on where to get help, and several new chapters covering a variety of topics.

It's serious non-fiction, dealing with how caregivers and patients can cope with serious disease — accented by occasional humorous distractions.

Woody Weingarten, a longtime voting member of the San Francisco Bay Area Theater Critics Circle, can be contacted via his revitalized website, https://woodyweingarten.com, or his email, voodee@sbcglobal.net.  His other three books include MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of his newspaper columns; and a whimsical fantasy intended for 6- to 10-year-olds that he co-authored with his then 8-year-old granddaughter.

Saturday, October 24, 2026

Scientists study cancer vaccines for multiple cancers, announce one ready for melanoma

A first-of-its-kind experimental vaccine for melanoma has ushered in new hope for cancer patients.

Scientists are also studying cancer vaccines for brain cancer, pancreatic cancer and more, a story by Nina Agrawal in yesterday's editions of The New York Times is headlined.

How Robert F. Kennedy Jr., U.S. Secretary of Health and Human Services, who is notoriously anti-vaccine, feels about the breakthrough has not been revealed.

The article indicates that Merck and Moderna, the two drug manufacturers who developed the new vaccine, have "announced that patients with melanoma who received a vaccine tailored to help their immune systems attack their tumors were 42 percent less likely to experience a recurrence of the cancer within two years than those who did not receive the vaccine."

Dr. Robert Vonderheide
The Times piece quotes Dr. Robert Vonderheide, president-elect of the American Association for Cancer Research and director of the Cancer Center of the University of Pennsylvania, as saying, "This is the first step…Do we have as lot to learn. For sure."

The two companies, the story continues, "delivered their vaccine in combination with pembrolizumab (Keytruda). The medication is part of a relatively new class of drugs called immune checkpoint inhibitors, which take the brakes off important immune cells so they can attack cancer cells once they recognize them."

More information on clinical trials can be found in the second edition of Rollercoaster: How a caregiver can survive his partner’s breast cancer or any other lethal disease, a VitalityPress book that I, Woody Weingarten, recently finished rewriting. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details.

Wednesday, October 21, 2026

After Pope Leo XIV leaves hospital, his doctors say he won't need more lung cancer treatments

Pope Leo XIV
Since Pope Leo XIV's follow-up tests confirmed his disease was localized, his doctors say he won't need any further treatment for lung cancer.

The 71-year-old pontiff's surgery confirmed he had adenocarcinoma, the most common type of lung cancer.

The pope was discharged  from Rome's Gemelli Polyclinic four days after the operation in which the lower lobe of his right lung was removed in "the first major health event of his 17-month pontificate," according to an Associated Press story online today.

Surgery, the article says, "often can be enough when tumors are caught very early, such as when somehow an X-ray or other scan shows a spot long before it's large or causing symptoms…The pope appears to have had one of those 'incidental findings,'" a nodule in his lung spotted during another exam" for potential abdominal abnormalities.

The AP dispatch also says that "the pope carried on business while in the hospital, including a call with Russian President Vladimir Putin, and has appeared strong in two public appearances at the Vatican since the surgery."

More information on life-threatening illnesses can be found in the second edition of Rollercoaster: How a caregiver can survive his partner’s breast cancer or any other lethal disease, a VitalityPress book that I, Woody Weingarten, recently finished rewriting. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details. 

Friday, September 4, 2026

'Magic mushrooms' may prevent nerve damage caused by chemotherapy, research on mice finds

Although the latest research on psilocybin was conducted in mice, clinical trials on humans are scheduled to begin this month.

That's a big deal — because the preliminary study found that the hallucinogenic compound known as "magic mushrooms' may prevent nerve damage caused by chemotherapy.

A story by Andrew Jacobs in yesterday's editions of The New York Times says "a study published…in the journal Science makes a compelling case that administering psilocybin shortly before cancer treatments might prevent chemotherapy-induced peripheral neuropathy, a condition that affects about two-thirds of patients who receive chemo."

If the trials are successful, the story claims, "the treatment could revolutionize cancer therapy and improve the quality of life for millions."

Peripheral neuropathy, for which there are currently no effective treatments, "causes pain, tingling and numbness in the hands and feet, and can force patients to scale back or halt chemotherapy when the discomfort becomes too much to bear," he article explains.

For some patients, the pain and discomfort never goes away.

Patrick Dougherty
"The good news," the story quotes Patrick Dougherty a pain medicine researcher at Texas MD Anderson Cancer Center and an author of the study, is that after getting chemo treatments "you're cured of your cancer. The bad news is your hands and feet are going to feel like they're burning the rest of your life. This is not what people want."

Psilocybin, which remains illegal at the federal level, has already shown increasing promise for treating depression, anxiety, end-of-life distress and other mental health challenges," the Times article proclaims.

More information on clinical trials can be found in Rollercoaster: How a man can survive his partner's breast cancer, aVitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details.

 

Thursday, August 27, 2026

FDA okays pill that can help pancreatic cancer patients live twice as long as having chemo

The FDA yesterday approved Daraxonrasib, which in a clinical trail had shown that advanced pancreatic cancer patients could live twice as long as those who got chemotherapy.

The drug is poised to transform care for the disease, according to a story by Gina  Kolata, Rebecca Robbins, and Carolyn Y. Johnson in today's editions of The New York Times. Daraxonrasib, the article says, "is not a cure, but it is the first treatment to substantially extend the lives of patients with pancreatic cancer."

The breakthrough drug, which will be sold under the brand name Rasonque, was approved for patients with metastatic pancreatic cancer who already tried chemo.

Dr. Anna Berkenblit
"We've never seen a benefit like this," the story quotes Dr. Anna Berkenblit, chief scientific and medical officer at the Pancreatic Cancer Action Network, an advocacy group for research and patients.

The costly drug, which is taken twice a day, will have "a sticker price of $39,800 a month, or about $478,000 when patients take it for a full year," the Times piece reports. The vast majority of the cost  is expected to be covered through insurance.

Pancreatic cancer kills more than 50,000 people in the United States annually.

The researcher who led the key study, Dr. Brian Wolpin of the Dana-Farber Cancer Institute in Boston, the article notes, "said in an interview that he was stunned by the trial results..."I have not seen anything like [them] before in trials we have run...I just kept repeating, 'Wow.'" 

But Daraxonrasib, the story continues, "often causes side effects like rash, diarrhea, fatigue, and nausea. Several patients who took the drug in clinical trials said the side effects could be harsh."

More information on clinical trials can be found in Rollercoaster: How a man can survive his partner's breast cancer, aVitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details.

Wednesday, July 29, 2026

Updated 'Rollercoaster,' a tribute to cancer patient Nancy Fox, slated for August publication

The second edition of Rollercoaster should be ready for a curious public next month. 

With its first major revision in 15 years, the book, which now carries the adjusted subtitle How a man can survive his partner’s breast cancer or any other lethal disease, is up-to-the-minute insofar as medicines, treatments, and where to find help are concerned.

 

The volume, first of four I, Woody Weingarten, wrote since becoming a “retired” elder, contains several totally new chapters. It also features massive rewrites in virtually every other segment. 

Nancy and Woody, circa 1997

Nancy Fox, my musical-genius wife and muse who successfully battled breast cancer for more than three decades, is the heroine of Rollercoaster, a real-life love story and memoir. 


In effect, it is a tribute to her courage and ability to laugh and to genuinely enjoy her life despite having to forever fight off dangerous cells.


Anyone who wants to find information about my other three books should check out my website, www.woodyweingarten.com. 

 

Highlighted there are MysteryDates: How to keep the sizzle in your relationship; The Roving I, which features 70 favorite newspaper columns I penned; and Grampy and His Fairyzona Playmates, a children’s fantasy aimed at 6- to 10-year-olds that was co-written by my then-8-year-old granddaughter, Hannah Schifrin.

Monday, July 13, 2026

Scientists identify proteins that can predict lung cancers more than five years before diagnosis

"Early research suggests a path to predict and prevent lung cancer."

That was the headline of a recent story by Nina Agrawal that appeared on the online site of The New York Times. 

The subhead? "Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the odds of a tumor developing."

A team of more than 80 researchers "working across four continents have identified a set of proteins in the blood that accurately predict lung cancers more than five years before diagnosis," the story says.

It indicates, too, that the scientists "also found early evidence that an existing anti-inflammatory drug [canakinumab] could significantly reduce lung cancer risk in people with elevated concentrations of these proteins, which they linked to inflammation."

The findings were published in the journal Cell. Lung cancer, the Times story says, "kills more people worldwide than any other cancer." Fewer than one-third of people diagnosed survive past five years.

Dr. Charles Swanton
"Prevention is the solution in my mind," the article quotes Dr. Charles Swanton, oncologist and director of the Francis Crick Institute in the United Kingdom who was senior author of the  paper. 

Swanton, who recently joined the board of Novartis, the maker of canakinumab, also contends that the findings suggest "smoke causes mutations and inflammation, which together cause cancer."

The drug, according to the story, "nearly halved the risk of lung cancer among 2,300 patients in the trial who had higher-than-average expression of the 14 proteins."

Dr. Peter Mazzone, a pulmonologist at the Cleveland Clinic, on the other hand, offers a massive caveat. He's quoted as warning about canakinumab's potential side effects, including increased risk of infection and sepsis, and says that "even within a narrow population, it could still be too toxic for the benefit to outweigh the harms. It's possible that a different medicine that targets the same pathway could work and would be safer." 

More information on new research can be found in Rollercoaster: How a man can survive his partner's breast cancer, aVitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details.

Tuesday, July 7, 2026

Half of the patients with advanced lung cancer, America's deadliest, reject treatment, study says

Fifty-two percent of metastatic lung cancer patients fail to get life-extending treatments, a new study finds.

According to a recent story by Simar Bajaj in The New York Times, the reason they skip such treatments as chemotherapy, immunotherapy. and targeted therapy is, experts suggest, because of "access issues, fatalism, and shame."

The Times article reports that the study, published in JAMA Oncology, "analyzed more than 250,000 people on Medicare between 2006 and 2021, with an average age of 73, and found that the proportion of patients who received these treatments increased only slightly over time, to 48 percent from 45 percent."

More than 110,000 Americans are annually diagnosed with metastatic lung cancer, the deadliest cancer in the United States.

Dr. Carolyn J. Presley
But over the past 15 years, Dr. Carolyn J. Presley, chief of thoracic medical oncology at Ohio State University (who wasn't involved in the study ), is quoted, dozens of promising new drugs have come to market. For some patients, a pill can hold the disease in check for years, "so the fact that so many older adults are not getting treatment is really, really sobering."

Some patients who smoked "might feel like they brought this disease upon themselves," Bajaj's story says,  and — according to Dr. Adam Fox, pulmonologist at the Medical University of South Carolina, who led the study — the stigma not only contributes to diagnostic delays but also to patients feeling unworthy of care.

Fatalism, the lingering belief that metastatic lung cancer is hopeless and treatment is unlikely to help, might be adopted by some primary care and emergency medicine doctors, the article suggests.

As for access issues, "one of the biggest barriers to treatment is not being diagnosed in time. Screening can catch tumors early, but it remains widely underutilized, largely because most people don't know it's available and complicated eligibility criteria make it difficult for docs to figure out who qualifies," Bajaj's piece notes.

More information on Stage 4, metastasized disease can be found in Rollercoaster: How a man can survive his partner's breast cancer, aVitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my other website at https://woodyweingarten.com for details.